Search
Insight Molecular Diagnostics Ord Shs
IMDXAdd to Watchlist
3.915USD
+0.005+0.13%
Market hours 09/24, 14:30（ET）
126.42MMarket Cap
LossP/E TTM
Insight Molecular Diagnostics Ord Shs (IMDX) Stock Price Target & Forecast
Analyst Rating
Based on 5 analysts
Buy
0 Strong Buy
3 Buy
2 Hold
0 Sell
0 Strong Sell
Target Price
9.667USD+133.49%
IMDX Analyst Recommendation Trends
In the current month, IMDX has received 3 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. IMDX average Analyst price target in the last month is 9.667.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
0
0
0
0
0
0
0
0
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5
5
4
4
4
4
4
4
IMDX Analyst Rating for Peer Comparison
Updated: Sep 23, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
Insmed Inc
INSM
7
17
0
0
0
24
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Cytokinetics Inc
CYTK
4
16
2
0
0
22
CRISPR Therapeutics AG
CRSP
4
8
10
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, IMDX EPS is projected to reach -0.236 in FY2026Q3, following reported EPS of -0.306 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.24
-0.26
-0.24
-0.24
-0.23
Actual
-0.72
-0.12
-0.31
--
--
Surprise
-201.57%
+52.47%
-25.44%
--
--
FAQs
What is Insight Molecular Diagnostics Ord Shs's expected revenue for the next quarter?
Insight Molecular Diagnostics Ord Shs's expected revenue is 244.20K.
What is Insight Molecular Diagnostics Ord Shs's price target?
Analysts forecast that Insight Molecular Diagnostics Ord Shs's price target is USD 9.67, with the highest forecast at USD 12.00 and the lowest forecast at USD 8.00.
How have Insight Molecular Diagnostics Ord ShsIMDX's recent earnings per share performed?
The market expectation was USD -0.31, while Insight Molecular Diagnostics Ord ShsIMDX's earnings per share (EPS) for the previous quarter was USD -0.12. EPS for the next quarter is expected at USD -0.24.
What is the analyst rating for Insight Molecular Diagnostics Ord Shs?
Based on the ratings of Insight Molecular Diagnostics Ord Shs's stock from 5 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.